Literature DB >> 32634277

Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels.

Janet Crane1, Jackie Manfredo1, Elisa Boscolo2, Mara Coyan3, Clifford Takemoto4, Maxim Itkin5, Denise M Adams6, Timothy D Le Cras3.   

Abstract

Kaposiform lymphangiomatosis (KLA) is a rare, life-threatening congenital lymphatic malformation. Diagnosis is often delayed due to complex indistinct symptoms. Blood angiopoietin-2 (ANG2) levels are elevated in KLA and may be useful as a biomarker to monitor disease status. We report a 7-year-old male child with easy bruising, inguinal swelling, and consumptive coagulopathy, diagnosed with KLA. A multimodal treatment regimen of prednisone, sirolimus, vincristine, and adjunctive zoledronate was used. Plasma ANG2 levels were highly elevated at diagnosis but decreased during treatment. The patient showed significant clinical improvement over a 38-month period and normalization of ANG2 levels correlated with resolution of the coagulopathy.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiogenesis; vascular malformations; vincristine

Mesh:

Substances:

Year:  2020        PMID: 32634277     DOI: 10.1002/pbc.28529

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

Authors:  Guy Chowers; Gadi Abebe-Campino; Hana Golan; Asaf Vivante; Shoshana Greenberger; Michalle Soudack; Galia Barkai; Ilana Fox-Fisher; Dong Li; Michael March; Mark R Battig; Hakon Hakonarson; Denise Adams; Yoav Dori; Adi Dagan
Journal:  Pediatr Res       Date:  2022-03-04       Impact factor: 3.953

2.  Sirolimus in the treatment of kaposiform lymphangiomatosis.

Authors:  Jiangyuan Zhou; Kaiying Yang; Siyuan Chen; Yi Ji
Journal:  Orphanet J Rare Dis       Date:  2021-06-08       Impact factor: 4.123

Review 3.  Osteopathy in Complex Lymphatic Anomalies.

Authors:  Ernesto Solorzano; Andrew L Alejo; Hope C Ball; Joseph Magoline; Yusuf Khalil; Michael Kelly; Fayez F Safadi
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.